Covered recipient · General Payments record
PAMELA KUZERA
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,695.87
- Reported across 94 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $396.01 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| DEXCOM, INC. | $133.36 | 1 |
| Lilly USA, LLC | $66.41 | 4 |
| ABBVIE INC. | $63.85 | 4 |
| Amgen Inc. | $33.56 | 2 |
| GlaxoSmithKline, LLC. | $28.18 | 2 |
| Abbott Laboratories | $19.53 | 1 |
| Novo Nordisk AS | $18.63 | 1 |
| Acerta Pharma LLC | $16.41 | 1 |
| Exact Sciences Corporation | $16.08 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.53 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124997035 | CMS |
| ABBVIE INC. | $15.53 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107494642 | CMS |
| ABBVIE INC. | $13.50 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107494644 | CMS |
| ABBVIE INC. | $14.34 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107494646 | CMS |
| ABBVIE INC. | $20.48 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107494648 | CMS |
| Amgen Inc. | $16.12 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117604345 | CMS |
| Amgen Inc. | $17.44 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117604347 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.41 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104237381 | CMS |
| Dexcom, Inc. | $133.36 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153381872 | CMS |
| Exact Sciences Corporation | $16.08 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114745250 | CMS |
| GlaxoSmithKline, LLC. | $13.73 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116565722 | CMS |
| GlaxoSmithKline, LLC. | $14.45 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115851912 | CMS |
| Lilly USA, LLC | $18.07 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135853335 | CMS |
| Lilly USA, LLC | $17.10 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135940378 | CMS |
| Lilly USA, LLC | $13.65 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135918308 | CMS |
| Lilly USA, LLC | $17.59 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135898336 | CMS |
| Novo Nordisk Inc | $18.63 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100260351 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.